trending Market Intelligence /marketintelligence/en/news-insights/trending/QoIdRLhl1sX7-il9YLdY6w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sun Pharma to acquire Novartis cancer drug Odomzo for $175M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Sun Pharma to acquire Novartis cancer drug Odomzo for $175M

India's Sun Pharmaceutical Industries Ltd. agreed to buy Novartis AG's oncology drug Odomzo for an upfront payment of $175 million plus future milestone payments.

The agreement, which was signed between units of both parties, is subject to antitrust clearance and other closing conditions.

Odomzo, which received FDA approval in July 2015, is used to treat adult patients with locally advanced basal cell carcinoma that recurred after surgery or radiation therapy, or those who are not qualified for surgery or radiation therapy.

Sun Pharma said that the acquisition will support its expansion into branded oncology, adding that the drug has global potential. Odomzo has marketing approval in more than 30 countries.